309 related articles for article (PubMed ID: 33849780)
1. Efficacy of mepolizumab in elderly patients with severe asthma and overlapping COPD in real-world settings: A retrospective observational study.
Isoyama S; Ishikawa N; Hamai K; Matsumura M; Kobayashi H; Nomura A; Ueno S; Tanimoto T; Maeda H; Iwamoto H; Hattori N
Respir Investig; 2021 Jul; 59(4):478-486. PubMed ID: 33849780
[TBL] [Abstract][Full Text] [Related]
2. REal worlD Effectiveness and Safety of Mepolizumab in a Multicentric Spanish Cohort of Asthma Patients Stratified by Eosinophils: The REDES Study.
Domingo Ribas C; Carrillo Díaz T; Blanco Aparicio M; Martínez Moragón E; Banas Conejero D; Sánchez Herrero MG;
Drugs; 2021 Oct; 81(15):1763-1774. PubMed ID: 34586602
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of mepolizumab in a real-world cohort of patients with severe eosinophilic asthma.
Pertzov B; Unterman A; Shtraichman O; Shitenberg D; Rosengarten D; Kramer MR
J Asthma; 2021 Jan; 58(1):79-84. PubMed ID: 31479312
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of mepolizumab treatment in oral corticosteroid-dependent severe eosinophilic asthma patients with chronic rhinosinusitis with nasal polyps: single center, real life study.
Yilmaz I; Türk M; Nazik Bahçecioğlu S; Tutar N; Gülmez I
Turk J Med Sci; 2020 Apr; 50(2):433-441. PubMed ID: 32093447
[TBL] [Abstract][Full Text] [Related]
5. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis.
Kallieri M; Zervas E; Katsoulis K; Fouka E; Porpodis K; Samitas K; Papaioannou AI; Kipourou M; Gaki E; Vittorakis S; Markatos M; Dimakou K; Ampelioti S; Koukidou S; Makris M; Ntakoula M; Mitrova MH; Glynos K; Antoniou KM; Gaga M; Tzanakis N; Markopoulou K; Papakosta D; Bakakos P; Loukides S
Int Arch Allergy Immunol; 2020; 181(8):613-617. PubMed ID: 32570256
[TBL] [Abstract][Full Text] [Related]
6. Results in clinical practice in the treatment of severe eosinophilic asthma with mepolizumab: a real-life study.
Enríquez-Rodríguez AI; Hermida Valverde T; Romero Álvarez P; López-González FJ; Gullón Blanco JA; Expósito Villegas AR; Escobar Fernández MJ; Beristáin Urquiza AM; Alonso Fernández MÁ; Gutiérrez Rodríguez M; Castaño De Las Pozas G; Jiménez Pérez J; Fernández Mellado R; García Clemente MM; Casan Clara P
J Asthma; 2022 May; 59(5):1005-1011. PubMed ID: 33653213
[TBL] [Abstract][Full Text] [Related]
7. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
8. Mepolizumab for severe eosinophilic asthma: a real-world snapshot on clinical markers and timing of response.
Caminati M; Cegolon L; Vianello A; Chieco Bianchi F; Festi G; Marchi MR; Micheletto C; Mazza F; Tognella S; Senna G
Expert Rev Respir Med; 2019 Dec; 13(12):1205-1212. PubMed ID: 31592700
[No Abstract] [Full Text] [Related]
9. Mepolizumab Is an Effective Option in Severe Eosinophilic Asthma Regardless of Baseline Features: Single-Center Real-Life Data.
Özdel Öztürk B; Yavuz Z; Eraslan D; Mungan D; Demirel YS; Aydın Ö; Sin BA; Bavbek S
Int Arch Allergy Immunol; 2022; 183(5):526-538. PubMed ID: 34915496
[TBL] [Abstract][Full Text] [Related]
10. Mepolizumab add-on therapy in a real world cohort of patients with severe eosinophilic asthma: response rate, effectiveness, and safety.
van Toor JJ; van der Mark SC; Kappen JH; In 't Veen JCCM; Braunstahl GJ
J Asthma; 2021 May; 58(5):651-658. PubMed ID: 31999203
[No Abstract] [Full Text] [Related]
11. Disease burden and efficacy of mepolizumab in patients with severe asthma and blood eosinophil counts of ≥150-300 cells/μL.
Yancey SW; Bradford ES; Keene ON
Respir Med; 2019 May; 151():139-141. PubMed ID: 31047111
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of the Clinical Features and Laboratory Data of Patients with Severe Eosinophilic Asthma Classified as Super-Responders, Partial Responders, or Nonresponders to Mepolizumab Treatment: A Real-Life Study.
Cakmak ME; Öztop N; Yeğit OO; Özdedeoğlu Ö
Int Arch Allergy Immunol; 2023; 184(8):736-743. PubMed ID: 36996772
[TBL] [Abstract][Full Text] [Related]
13. Anti-IL5/IL5R Treatment in COPD: Should We Target Oral Corticosteroid-Dependent Patients?
Laroche J; Pelletier G; Boulay MÈ; Côté A; Godbout K
Int J Chron Obstruct Pulmon Dis; 2023; 18():755-763. PubMed ID: 37180748
[TBL] [Abstract][Full Text] [Related]
14. Switching Treatment from Mepolizumab to Benralizumab for Elderly Patients with Severe Eosinophilic Asthma: A Retrospective Observational Study.
Isoyama S; Ishikawa N; Hamai K; Matsumura M; Kobayashi H; Nomura A; Ueno S; Tanimoto T; Maeda H; Iwamoto H; Hattori N
Intern Med; 2022; 61(11):1663-1671. PubMed ID: 35650114
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis.
Numata T; Nakayama K; Utsumi H; Kobayashi K; Yanagisawa H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2019 Oct; 19(1):176. PubMed ID: 31606052
[TBL] [Abstract][Full Text] [Related]
16. Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma.
Khatri S; Moore W; Gibson PG; Leigh R; Bourdin A; Maspero J; Barros M; Buhl R; Howarth P; Albers FC; Bradford ES; Gilson M; Price RG; Yancey SW; Ortega H
J Allergy Clin Immunol; 2019 May; 143(5):1742-1751.e7. PubMed ID: 30359681
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of benralizumab for patients with severe eosinophilic asthma: a retrospective, real-life study.
Numata T; Miyagawa H; Nishioka S; Okuda K; Utsumi H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2020 Aug; 20(1):207. PubMed ID: 32746787
[TBL] [Abstract][Full Text] [Related]
18. Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma.
Comberiati P; McCormack K; Malka-Rais J; Spahn JD
J Allergy Clin Immunol Pract; 2019; 7(8):2689-2696.e2. PubMed ID: 31201938
[TBL] [Abstract][Full Text] [Related]
19. Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment.
Magnan A; Bourdin A; Prazma CM; Albers FC; Price RG; Yancey SW; Ortega H
Allergy; 2016 Sep; 71(9):1335-44. PubMed ID: 27087007
[TBL] [Abstract][Full Text] [Related]
20. Real-life effectiveness of mepolizumab in severe asthma: a systematic literature review.
Israel E; Canonica GW; Brusselle G; Yang S; Howarth PH; Martin AL; Koufopoulou M; Smith SG; Alfonso-Cristancho R
J Asthma; 2022 Nov; 59(11):2201-2217. PubMed ID: 34951336
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]